Kavita Nair, PhD, FAAN, discusses academic medical centers' unique role in diagnosing and managing neurodegenerative diseases ...
Takenobu Y, Kikuchi T, Ishikawa D, et al. Rozanolixizumab as rescue therapy in triple seronegative refractory generalized ...
Plozasiran is the first FDA-approved drug for familial chylomicronemia syndrome, reducing triglycerides as an adjunct to diet ...
Her study, "Medicare Advantage Reimbursement Structures Impact Home Health Delivery and Outcomes," explores how home health ...
Clark Alsfeld, MD, discusses how telemedicine, pharmacists, and evolving policies help overcome financial and geographic ...
Patients seeking access to oral acute myeloid leukemia (AML) medications face complex insurance approval processes that can ...
Panelists discuss how managing oral therapy toxicities requires preemptive planning, multidisciplinary team involvement, ...
Panelists discuss how prescription digital therapeutics like Daylight show promise for treating depression and anxiety but ...
Women under age 50 who consume higher amounts of ultraprocessed foods (UPFs) face significantly increased odds of developing ...
Panelists discuss how digital therapeutics could address the enormous unmet need for treating negative symptoms in the 60% of ...
Jasmine Eugene, PharmD, explains how pharmacists practicing at the top of their license improve rural oncology access and ...
GLP-1 RAs, particularly semaglutide and tirzepatide, outperform older medications in achieving significant weight loss in adults with and without type 2 diabetes. Semaglutide and tirzepatide met ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback